Investigational drug · Phase 2
HS-10516
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Clear Cell Renal Cell Carcinoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 1, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "HS-10516"
First trial start
2025
Jul 10, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HS-10516", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Clear Cell Renal Cell Carcinoma
Approved drugs for the same conditions: Kidney cancer (renal cell carcinoma) · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "HS-10516" as an intervention, largest first.
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT06049030 · 190 participants (planned) · Start Sep 25, 2023 · Primary completion Sep 25, 2024
Drug: HS-10516 · For: Renal Cell Carcinoma
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT07097935 · 104 participants (planned) · Start Jul 10, 2025 · Primary completion Jul 10, 2027
Drug: HS-10516 + Lenvatinib · For: Advanced Clear Cell Renal Cell Carcinoma
Sites: Beijing, China
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT06553339 · 60 participants (planned) · Start Jul 19, 2024 · Primary completion Jul 31, 2026
Drug: Oral HS-10516 · For: Von Hippel Lindau-Deficient Clear Cell Renal Cell Carcinoma
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Advanced Clear Cell Renal Cell Carcinoma
- CasdatifanAB521Phase 33 trials
Arcus Biosciences, Inc. · Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma (RCC)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.